CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Olaparibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02677038
NCT02677038Phase 2Completed
CompareCT.gov

Olaparib for BRCAness Phenotype in Pancreatic Cancer: Phase II Study

M.D. Anderson Cancer Center·interventional·Posted Feb 9, 2016·Updated Oct 1, 2024

In Brief

A Phase 2 clinical trial evaluating Olaparib for Metastatic Pancreatic Adenocarcinoma and 2 related conditions. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This phase II trial studies how well olaparib works in treating patients with stage IV pancreatic cancer. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), AstraZeneca

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 9, 2016
Enrollment StartNov 11, 2016
Primary CompletionJul 18, 2022
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 10.4 years ago

Interventions

Olaparibdrug

Given PO